文献速递膀胱癌与上尿路尿路上皮癌

阿替利珠单抗治疗卡介苗无反应高危非肌层浸润性膀胱癌的2期试验:SWOG S1605

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
PubMed 文献 · Eur Urol · 2023-08-16

这项单臂2期试验评估静脉阿替利珠单抗(每3周一次,持续1年)治疗卡介苗无反应高危非肌层浸润性膀胱癌的疗效与安全性,患者为不适合或拒绝根治性膀胱切除术者。74例原位癌患者6个月病理完全缓解率为27%,55例Ta/T1患者18个月无事件生存率为49%(90%CI 38-60%)。疗效未达到预设阈值,3-5级治疗相关不良事件发生率为16%(26例),包括3例治疗相关死亡。

要点

  • 卡介苗无反应高危非肌层浸润性膀胱癌中,阿替利珠单抗6个月病理完全缓解率为27%(20/74例原位癌患者)。
  • 55例Ta/T1患者18个月无事件生存率为49%(90%CI 38-60%),129例可评估患者中12例进展为肌层浸润或转移性疾病。
  • 3-5级治疗相关不良事件发生于26例(16%),包括3例治疗相关死亡,疗效未达预设阈值。

核心结论

  • 阿替利珠单抗在卡介苗无反应高危非肌层浸润性膀胱癌中的疗效与类似药物的试验结果相似,但未达到预设的疗效阈值。
  • 在早期膀胱癌中考虑全身免疫治疗时,其适度疗效需与显著的治疗相关不良事件发生率和疾病进展风险相权衡。

研究设计与样本

  • 单臂2期试验,纳入卡介苗无反应高危非肌层浸润性膀胱癌且不适合或拒绝根治性膀胱切除术的患者。
  • 共入组172例患者,166例至少接受一剂阿替利珠单抗(安全性分析),129例符合条件(疗效分析)。
  • 干预为静脉阿替利珠单抗每3周一次,持续1年。
  • 主要终点为原位癌患者经6个月强制活检确定的病理完全缓解率;非原位癌肿瘤患者18个月无事件生存率和治疗相关不良事件为关键次要终点。

主要发现

  • 74例原位癌患者中20例(27%)在6个月时达到完全缓解,中位缓解持续时间为17个月,56%(95%CI 34-77%)的缓解持续至少12个月。
  • 55例Ta/T1疾病患者18个月 actuarial 无事件生存率为49%(90%CI 38-60%)。
  • 129例可评估患者中12例出现进展为肌层浸润或转移性疾病。
  • 26例(16%)发生3-5级治疗相关不良事件,包括3例治疗相关死亡。

关键数值与推荐

  • 主要终点:原位癌患者6个月病理完全缓解率为27%(20/74)。
  • 关键次要终点:Ta/T1患者18个月无事件生存率为49%(90%CI 38-60%)。
  • 3-5级治疗相关不良事件发生率为16%(26/166例安全性分析人群),其中治疗相关死亡3例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量小。
  • 患者不符合条件率高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although radical cystectomy (RC) is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), many patients are ineligible for surgery or elect bladder preservation. OBJECTIVE: To evaluate the efficacy and safety of atezolizumab in BCG-unresponsive high-risk NMIBC. DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm phase 2 trial in patients with BCG-unresponsive high-risk NMIBC who were ineligible for or declined RC. INTERVENTION: Intravenous atezolizumab every 3 wk for 1 yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the pathological complete response (CR) rate for patients with carcinoma in situ (CIS) determined via mandatory biopsy at 6 mo. Event-free survival (EFS) at 18 mo for patients with non-CIS tumors and treatment-related adverse events (TRAEs) were key secondary endpoints. RESULTS AND LIMITATIONS: Of 172 patients enrolled in the trial, 166 received at least one dose of atezolizumab (safety analysis) and 129 were eligible (efficacy analysis). Of the 74 patients with CIS, 20 (27%) experienced a CR at 6 mo. The median duration of response was 17 mo, and 56% (95% confidence interval [CI] 34-77%) of the responses were durable to at least 12 mo. The 18-mo actuarial EFS rate among 55 patients with Ta/T1 disease was 49% (90% CI 38-60%). Twelve of 129 eligible patients experienced progression to muscle-invasive or metastatic disease. Grade 3-5 TRAEs occurred in 26 patients (16%), including three treatment-related deaths. The study was limited by the small sample size and a high rate of patient ineligibility. CONCLUSIONS: The efficacy of atezolizumab observed among patients with BCG-unresponsive NMIBC is similar to results from similar trials with other agents, but did not meet the prespecified efficacy threshold. Modest efficacy needs to be balanced with a significant rate of TRAEs and the risk of disease progression when considering systemic immunotherapy in early-stage bladder cancer. PATIENT SUMMARY: We tested intravenous immunotherapy (atezolizumab) in patients with high-risk non-muscle-invasive bladder cancer that recurred after BCG (bacillus Calmette-Guérin) treatment. Although we found similar outcomes to previous trials, the benefit of this therapy is modest and needs to be carefully balanced with the significant risk of side effects. This trial is registered on ClinicalTrials.gov as NCT02844816.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Black PC, Tangen CM, Singh P, et al. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023. PMID: 37596191. doi:10.1016/j.eururo.2023.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。